Boltz and Pfizer Announce Strategic Collaboration to Develop and Deploy State-of-the-Art Biomolecular AI Foundation Models
CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced a strategic collaboration to empower scientists across the company with state-of-the-art biomolecular AI foundation models and generative workflows for small-molecule and biologics design. Boltz's open-source biomolecular foundation models (Boltz-2, BoltzGen) are very popular AI tools in the pharmaceutical industry for protein design, biomolecular structure prediction, and...